Aculeacin A is used to study mutations that lead to antibiotic resistance in Saccharomyces cerevisiae, the inhibition of Candida albicans and the morphogenetic transformation of Candida albicans when treated. Aculeacin A is a lipopeptide that inhibits β-glucan synthesis in yeasts. The inhibition is due to the selective blockage of glucan synthase. Aculeacin A, an amphophilic antibiotic, inhibits the biosynthesis of β−glucan by selective blockage of β(1→3) glucan synthase.
Ibrexafungerp citrate is a triterpenoid antifungal. Similarly to echinocandins, it inhibits the synthesis of 1,3-β-d-glucan. However, it binds to a different site on the enzyme than echinocandins, resulting in limited cross-resistance. Ibrexafungerp exerts concentration-dependent fungicidal activity against Candida species and retains in vitro activity against most fluconazole-resistant strains.